| 1999 |
The 17-amino acid middle-region peptide (Arg469–Arg485) of the NPR-C intracellular domain selectively binds Gi1 and Gi2, activates phospholipase C-β3 via βγ subunits, and inhibits adenylyl cyclase, identifying this sequence as the G protein-activating domain. A C-terminal BB-XX-B motif within this peptide mediates G protein binding but not activation. |
Synthetic peptide fragments of NPR-C cytoplasmic domain used in binding assays, adenylyl cyclase inhibition assays, PLC activity assays, and smooth muscle contraction assays |
The Journal of biological chemistry |
High |
10364194
|
| 2003 |
Mutational and deletion analysis of rat NPR-C confirmed that the 17-amino acid sequence R469–R485 in the middle region of the intracellular domain is both necessary and sufficient for G protein (Gi1/Gi2) and PLC-β activation and adenylyl cyclase inhibition. Substitution of N-terminal arginines (R469/R470) or C-terminal basic residues (H481, R482, R485) abolished activity. The 11 C-terminal residues (E486–A496) serve an autoinhibitory function. |
Site-directed mutagenesis and deletion mutagenesis of NPR-C intracellular domain expressed in cells; Gi1/Gi2 activity assays, PLC-β assay, adenylyl cyclase inhibition assay |
American journal of physiology. Cell physiology |
High |
12676657
|
| 2004 |
CNP and the selective NPR-C agonist cANF both significantly inhibit L-type Ca2+ current (ICa(L)) in sinoatrial node myocytes. Dialysis of a 17-amino acid Gi-activator peptide derived from NPR-C intracellular domain reproduced this inhibition, demonstrating that NPR-C couples to Gi to reduce ICa(L) and decrease heart rate. The hyperpolarization-activated current (If) was unaffected. |
Voltage-clamp electrophysiology on isolated SA node myocytes; intracellular dialysis of NPR-C-derived Gi-activator peptide; Langendorff-perfused heart ECG |
American journal of physiology. Heart and circulatory physiology |
High |
14704228
|
| 2005 |
CNP and cANF inhibit L-type Ca2+ current (~50%) and reduce action potential firing in magnocellular neurosecretory cells (MNCs) of the hypothalamus via NPR-C coupled to Gi protein, as demonstrated by mimicry with an intracellular Gi-activator peptide. T-type Ca2+ channels were unaffected. |
Whole-cell patch-clamp recordings in acutely isolated MNCs and slice preparation; intracellular dialysis of Gi-activator peptide |
Journal of neurophysiology |
High |
15772242
|
| 2005 |
Crystal structure of the NPR-C extracellular domain reveals a 1:2 hormone-to-receptor stoichiometry where the hormone intercalates at the interface of a receptor dimer, inducing a large-scale conformational change in membrane-proximal regions. This allosteric mechanism of hormone recognition is proposed to be conserved across the NPR family. |
X-ray crystallography of NPR-C ectodomain in quiescent and hormone-bound forms |
Peptides |
High |
15911071
|
| 1999 |
Three independent allelic mutations (lgj, stri, lgj2J) in mice that cause skeletal overgrowth (extended endochondral proliferation zone, elongated body) all map to and disrupt the Npr3 gene, establishing NPR-C as a required component of the natriuretic peptide clearance pathway that limits bone growth in vivo. |
Genetic mapping, allelism testing, skeletal preparation analysis, candidate gene identification by positional cloning |
Proceedings of the National Academy of Sciences of the United States of America |
High |
10468599
|
| 2016 |
An ENU-induced Tyr209Asn missense mutation in NPR3 introduces an aberrant N-linked glycosylation site, causing the protein to be retained in the endoplasmic reticulum and absent from the plasma membrane. Loss of plasma membrane NPR3 increases CNP availability for NPR2, elevating MAPK (p38) signaling in growth plate chondrocytes, expanding hypertrophic zones, and causing kyphosis with vertebral elongation. |
ENU mutagenesis screen; expression of wild-type and mutant NPR3 in COS-7 cells; immunohistochemistry for p38 MAPK phosphorylation; histomorphometric analysis of growth plates |
PloS one |
High |
27959934
|
| 2018 |
Bi-allelic loss-of-function mutations in NPR3 in humans (missense mutations p.Ser148Pro and p.Asp363Val causing intracellular retention; nonsense p.Tyr508* causing NMD) result in tall stature, long digits, extra epiphyses, and aortic dilatation. Biochemical analysis showed a reduced NTproNP/NP ratio and high cGMP, consistent with reduced natriuretic peptide clearance and consequent increased NPR-A/B signaling. |
Whole-exome sequencing; in vitro expression of mutant NPR-C to assess plasma membrane localization; plasma biochemistry (NTproNP/NP ratios, cGMP) |
American journal of human genetics |
High |
30032985
|
| 1999 |
A pentadecapeptide from the cytoplasmic region of NPR-C (closest to the membrane) suppressed calcium-evoked dopamine efflux ~40% in permeabilized PC12 cells, mimicking natriuretic peptide action. An antibody against this fragment abolished the neuromodulatory effect of CNP, and the C-terminal nonadecapeptide was inactive, localizing the neuromodulatory function to the proximal cytoplasmic domain. |
Intracellular delivery of receptor-derived peptides and antibodies in digitonin-permeabilized PC12 cells; dopamine efflux assay |
Endocrinology |
Medium |
10067834
|
| 2003 |
ANP stimulates exocrine pancreatic secretion in rats via NPR-C receptors (mimicked by cANP4-23) coupled to phosphoinositide hydrolysis (PLC pathway), not cAMP. The PLC inhibitor U-73122 blocked ANF-evoked phosphoinositide hydrolysis. Cholinergic, adrenergic, and nitric oxide pathways were not involved. |
In vivo pancreatic secretion in anesthetized rats with selective agonists; phosphoinositide hydrolysis assay in isolated acini; pharmacological blockade studies |
American journal of physiology. Gastrointestinal and liver physiology |
Medium |
12829435
|
| 2006 |
CNP stimulates amylase release from isolated pancreatic acini specifically through NPR-C (mimicked by cANP4-23, blocked by pertussis toxin), acting via the PLC pathway and IP3 receptors, not via cAMP or PKG. Higher CNP concentrations also reduced cAMP and increased cGMP, engaging NPR-A/B. |
Amylase secretion assay in isolated pancreatic acini with selective agonists/antagonists; PLC inhibitor (U-73122); IP3 receptor antagonist (2-APB); cAMP and cGMP measurement; pertussis toxin treatment |
American journal of physiology. Gastrointestinal and liver physiology |
Medium |
17702953
|
| 2006 |
ANP/cANP4-23 activation of NPR-C in kidney, aorta, heart, and atria increases NOS activity via Gi (blocked by pertussis toxin) and Ca2+-dependent calmodulin pathways (blocked by nifedipine and calmidazolium). In the atria, NPR-C appears to be the primary mediator of ANP-stimulated NOS activation. |
NOS activity assay (L-[14C]-arginine) in rat kidney, aorta, and heart; pharmacological blockade with pertussis toxin, nifedipine, calmidazolium |
Regulatory peptides |
Medium |
16712979
|
| 2006 |
NPR-C receptor localizes throughout porcine basilar artery including intramural nerves, and its activation produces NO-dependent vasodilation that is independent of the endothelium, implying NPR-C stimulates nNOS in intramural nerves to mediate vasodilation. |
Immunocytochemistry for receptor localization; vascular pharmacology with selective agonists; NOS inhibition (L-NAME); endothelial denudation |
Journal of cerebral blood flow and metabolism |
Medium |
15959462
|
| 2001 |
FGF-1, FGF-2, and PDGF-BB reduce NPR-C mRNA expression in pulmonary arterial smooth muscle cells via activation of tyrosine kinase receptors and MEK/ERK signaling (blocked by PD-166866, U-0126, and PD-98059), whereas hypoxia per se, Ang II, ET-1, ANP, and cGMP do not reduce NPR-C mRNA. |
Northern blot analysis of NPR-C mRNA in growth-arrested rat PASMCs treated with growth factors, kinase inhibitors, and other stimuli |
American journal of physiology. Lung cellular and molecular physiology |
Medium |
11404258
|
| 2001 |
In human thyrocytes, NPR-C (>97% of ANF binding sites) unexpectedly increases intracellular cAMP upon activation by ANP or cANF, contrasting with its canonical inhibitory coupling. This stimulatory cAMP response is absent in cells grown in low serum without pituitary/hypothalamic extracts. |
Radioligand binding (125I-ANF); cAMP measurement in human thyrocyte (HTU-5) cells with selective NPR-C agonist cANF; comparison with rat aortic smooth muscle cells |
Regulatory peptides |
Medium |
11164945
|
| 2011 |
NPR-C knockdown in murine embryonic stem cells causes apoptosis accompanied by induction of p53 protein. Chemical inhibition of p53 reduces apoptosis in NPR-C-deficient cells. Activation of NPR-C with cANF4-23 protects ES cells against oxidative stress-induced apoptosis by blocking p53 activation and Nanog suppression. |
siRNA knockdown of NPR-C; flow cytometry for apoptosis; Western blot for p53; p53 inhibitor α-pifithrin rescue experiment; cANF4-23 agonist treatment with oxidative stress challenge |
Stem cells and development |
Medium |
21846177
|
| 2016 |
NPR3 knockdown in H9C2 cardiomyocytes increases caspase-3, -8, and -9 activities, upregulates BRCA1 expression with predominantly cytoplasmic localization, increases CREB activity (positive regulator of BRCA1), and elevates TNF-α, activating both intrinsic and extrinsic apoptotic pathways. This identifies NPR3 as a suppressor of cardiomyocyte apoptosis acting through BRCA1 and TNF-α. |
Stable shRNA knockdown of NPR3 in H9C2 cells; caspase activity assays; Western blot and immunofluorescence for BRCA1 localization; CREB activity assay; TNF-α mRNA quantification |
Cell cycle (Georgetown, Tex.) |
Medium |
27494651
|
| 2002 |
Dietary salt supplementation selectively downregulates NPR-C mRNA by >60% in kidney (but not lung, brain, or heart) of both ANP+/+ and ANP-/- mice, demonstrating that this regulation is ANP-independent, and is accompanied by increased renal cGMP, suggesting local elevation of natriuretic peptide activity. |
Northern blot for NPR-C mRNA in multiple organs; cGMP measurement; comparison of ANP knockout vs wild-type mice on normal vs high-salt diets |
American journal of physiology. Renal physiology |
Medium |
11788435
|
| 2004 |
cAMP elevation (by forskolin or dibutyryl-cAMP) significantly increases NPR-C transcript levels in human aortic smooth muscle cells via a PKA-dependent mechanism (blocked by KT-5720), with functional upregulation confirmed by increased 125I-ANF binding competed by the NPR-C-specific ligand C-ANF(4-23). |
qRT-PCR; pharmacological activation/inhibition of cAMP/PKA pathway; radioligand binding assay |
Molecular and cellular endocrinology |
Medium |
15149737
|
| 2019 |
NPR-C knockout mice treated with angiotensin II show exacerbated atrial fibrillation susceptibility, prolonged action potential duration, reduced Vmax, and substantially greater atrial fibrosis compared to wild-type. NPR-C agonist cANF dose-dependently reduces AF inducibility and prevents Ang II-induced atrial electrophysiological changes and fibrosis, identifying NPR-C as a modulator of atrial structural and electrical remodeling. |
In vivo electrophysiology, high-resolution optical mapping, patch clamp, molecular biology in NPR-C-/- mice and wild-type mice ± Ang II ± cANF |
Circulation. Arrhythmia and electrophysiology |
High |
30636477
|
| 2017 |
NPR-C knockout mice exhibit elevated heart rate, reduced heart rate variability, enhanced arrhythmogenesis (sinus pauses), and decreased parasympathetic/increased sympathetic tone as assessed by HRV analysis and autonomic pharmacology (atropine/propranolol), establishing NPR-C as a regulator of autonomic control of heart rate. |
Telemetric ECG recording in awake mice; heart rate variability analysis (time and frequency domain); pharmacological autonomic blockade |
Scientific reports |
High |
29242602
|
| 2023 |
NPRC deletion in diabetic mice attenuates cardiac fibrosis by upregulating TGIF1 (which inhibits Smad2/3 phosphorylation), mediated by activation of cAMP/PKA and cGMP/PKG signaling downstream of NPRC deletion. NPRC knockdown in cardiac fibroblasts decreases collagen synthesis and proliferation. |
NPRC-/- diabetic mouse model; RNA sequencing; Western blot for Smad2/3 phosphorylation and TGIF1; in vitro knockdown in cardiac fibroblasts and cardiomyocytes |
Science advances |
High |
37531438
|
| 2023 |
NPRC deletion reduces atherosclerotic lesion size and instability in ApoE-/- mice. Mechanistically, NPRC deletion activates cAMP/PKA signaling, leading to upregulated AKT1 pathway and downregulated NF-κB pathway, reducing ROS, inflammation, and endothelial apoptosis while increasing eNOS expression. Endothelial cell-specific NPRC knockout recapitulates the protective effect, while endothelial overexpression aggravates lesions. |
Systemic and endothelial cell-specific NPRC KO in ApoE-/- mice; endothelial overexpression model; in vitro HAEC knockdown/overexpression; ROS, cytokine, NF-κB, AKT, eNOS pathway assays |
Signal transduction and targeted therapy |
High |
37553374
|
| 2021 |
NPRC (Npr3) in spinal dorsal horn neurons co-expresses with NMBR (neuromedin B receptor). BNP facilitates NMB-encoded histaminergic itch through a NPRC–NMBR cross-signaling mechanism: NPRC is required for histamine-evoked itch but not chloroquine-evoked itch, and BNP evokes Ca2+ responses in cells co-expressing NMBR and NPRC, suggesting NPRC signals via the Gq-PLC-Ca2+ pathway through NMBR crosstalk. |
In situ hybridization for co-localization; behavioral itch assays in Npr3 KO mice; Ca2+ imaging in NMBR/NPRC HEK293 cells and dorsal horn neurons |
eLife |
High |
34919054
|
| 2023 |
In Xenopus, Npr3 regulates neural crest (NC) and cranial placode (CP) progenitor formation through dual functions: (1) as a clearance receptor that modulates local natriuretic peptide concentrations for optimal cGMP production through Npr1 activation, and (2) as a signaling receptor that controls cAMP levels through inhibition of adenylyl cyclase, with differential regulation of NC vs. CP developmental programs. |
Morpholino-based knockdowns of Npr3, Npr1, Nppa, Nppc in Xenopus; pharmacological inhibitors; rescue assays; in situ hybridization |
eLife |
High |
37162198
|
| 2016 |
In Npr3-deficient mice, a small population (~13%) of dorsal root ganglion axons fail to form T-like bifurcation branches, suggesting Npr3 expressed by cells associated with dorsal roots (not DRG neurons themselves) contributes to normal sensory axon branching as a scavenger/clearance receptor regulating local CNP/cGMP levels. |
In situ hybridization, immunohistology, real-time cGMP imaging with fluorescent sensor, axon tracking in Npr3-deficient mice |
The European journal of neuroscience |
Medium |
27740716
|
| 2020 |
miR-146a directly targets NPR3 in adipocytes. CRISPR/Cas9-mediated knockout of NPR3 increases insulin-stimulated glucose uptake and enhances de novo lipogenesis in human SGBS adipocytes, identifying NPR3 as a functional downstream mediator of miR-146a in regulating adipocyte insulin sensitivity. |
miR-146a-/- mice on high-fat diet; miRNA mimic/inhibitor transfection; CRISPR/Cas9 KO of NPR3; glucose uptake assays; lipogenesis assays in SGBS adipocytes |
Cellular and molecular life sciences |
High |
33206203
|
| 2021 |
NPR3 overexpression in osteosarcoma cells inhibits PI3K/AKT pathway activity. NPR3 downregulation activates PI3K/AKT, promoting proliferation; this effect is reversed by PI3K/AKT pathway blockade. The transcription factor POU2F1 suppresses NPR3 promoter activity by binding the −900 to −800 bp region, reducing NPR3 expression. |
NPR3 overexpression and knockdown in OS cell lines; cell viability, cell cycle, apoptosis assays; Western blot for PI3K/AKT; dual-luciferase reporter and site-directed mutagenesis of NPR3 promoter; xenograft tumor experiments |
Cellular signalling |
Medium |
34229087
|
| 2024 |
NPRC promotes hepatic steatosis by recruiting the deubiquitinase USP30 via its ANPR domain; USP30 then deubiquitinates C/EBPβ at K149 (removing K48-linked polyubiquitin chains), stabilizing C/EBPβ and driving excessive lipid accumulation. The C/EBPβ DNA-binding domain interacts with USP30. |
Proteomic analysis, ubiquitination assay, Co-IP for NPRC-USP30 and USP30-C/EBPβ interactions, MeRIP; site-specific ubiquitination mapping |
Metabolism: clinical and experimental |
High |
39433172
|
| 2025 |
NPRC deficiency in podocytes reduces recycling and increases degradation of TGF-β receptor 2 (TGF-βR2), thereby suppressing TGF-β1/Smad2/3 signaling and attenuating glomerular fibrosis and podocyte injury in diabetic kidney disease. Podocyte-specific NPRC knockout mice showed reduced collagen synthesis and improved renal function. |
Podocyte-specific NPRC KO mice in diabetic model; mass spectrometry; ELISA; Western blot for Smad2/3 phosphorylation, TGF-βR2 expression and recycling; histological analysis |
Circulation research |
High |
40557490
|
| 2025 |
NPR-C deficiency in vascular smooth muscle cells (VSMC-specific KO) triggers thoracic aortic dissection under angiotensin II plus high-salt diet. Mechanistically, NPR-C loss activates ERK1/2, which reduces PPARγ expression and activity, downregulating HADHB (a mitochondrial trifunctional protein subunit for fatty acid oxidation), impairing mitochondrial homeostasis, and promoting extracellular matrix degeneration and VSMC apoptosis. |
VSMC-specific and endothelial cell-specific NPR-C KO mice; RNA-sequencing; Western blot for ERK1/2, PPARγ, HADHB; NPR-C agonist C-ANP4-23 treatment; spermidine (MTP activator) rescue |
Cardiovascular research |
High |
40377018
|
| 2024 |
Musclin binds NPR3 in pulmonary arterial smooth muscle cells, and NPR3 silencing reverses musclin-mediated inhibition of AKT phosphorylation and mTORC1 activity, glycolysis, oxidative stress, proliferation, and migration, establishing NPR3 as the receptor through which musclin exerts its protective anti-proliferative effects in PASMCs. |
Co-IP for musclin-NPR3 interaction; NPR3 siRNA silencing; mTORC1 activity assay; ECAR glycolysis assay; cell proliferation and migration assays in PASMCs |
Acta biochimica et biophysica Sinica |
Medium |
39632658
|
| 2025 |
Musclin induces NPR3–raptor interaction, which inhibits mTORC1 activity in VSMCs. NPR3 silencing abolishes musclin-mediated suppression of mTORC1, glycolysis, and VSMC phenotypic switching, establishing NPR3 as a scaffold that recruits raptor to inhibit mTORC1 and prevent vascular intimal hyperplasia. |
Co-IP for NPR3-raptor interaction; AAV6-mediated musclin overexpression in mouse vascular IH model; NPR3 siRNA; ECAR assay; VSMC differentiation marker expression |
Acta biochimica et biophysica Sinica |
Medium |
41074587
|
| 2025 |
In osteosarcoma cells, the E3 ubiquitin ligase UBE4A promotes ubiquitination and proteasomal degradation of NPR3 (a tumor suppressor). IGF2BP3 stabilizes UBE4A mRNA via m6A modification recognition, thereby indirectly reducing NPR3 levels and promoting OS malignancy. NPR3 overexpression reverses UBE4A-driven proliferation. |
RIP, MeRIP, RNA decay assays for IGF2BP3-UBE4A mRNA interaction; cell viability/apoptosis assays; Western blot; Co-IP/ubiquitination assay for UBE4A-NPR3 |
Physiology international |
Medium |
40674149
|
| 2022 |
NPR3 downregulation in osteosarcoma activates MAPK pathway (p38 MAPK and Erk1/2), impairing osteogenic differentiation of periodontal ligament stem cells under high glucose conditions. Inhibition of the NPR3-mediated p38 MAPK or Erk1/2 pathway enhances osteogenic differentiation. |
RNA-seq; lentivirus transfection for NPR3 modulation; Western blot for MAPK pathways; ALP staining/activity; Alizarin Red quantification; osteogenic differentiation assays |
Stem cell research & therapy |
Medium |
35841070
|
| 2025 |
NPR3 inhibits dental pulp stem cell (DPSC) colony formation, migration, and differentiation by positively regulating ERK1/2 phosphorylation. Ligustrazine (TMP) was identified as an NPR3 inhibitor, promoting DPSC functions; NPR3 overexpression or ERK1/2 inhibitor treatment abrogated TMP effects. |
NPR3 overexpression and knockdown in DPSCs; colony formation, migration, differentiation assays; Western blot for ERK1/2 phosphorylation; high-throughput drug screening; rescue experiments |
Experimental cell research |
Medium |
39984110
|
| 2025 |
In adipocyte-specific Nprc (Npr3) knockout mice subjected to HFpEF induction, adipocyte Nprc loss downregulates Wnt5a expression in visceral adipose tissue. Wnt5a exposure causes cardiomyocyte hypertrophy in vitro, and in vivo inhibition of Wnt ligand secretion (LGK974) reduces circulating Wnt5a and improves cardiac remodeling, identifying an adipocyte Nprc → Wnt5a → cardiomyocyte axis in HFpEF. |
Adipocyte-specific and cardiomyocyte-specific Nprc KO mice; 2-hit HFpEF model; echocardiography; bulk RNA-seq of adipose tissue; H9C2 Wnt5a treatment; in vivo LGK974 treatment |
bioRxivpreprint |
Medium |
bio_10.1101_2025.10.29.685456
|